Biogen Inc said on Thursday it will split its research and development division into two units ahead of a highly anticipated decision by the U.S. health regulator about the company's second Alzheimer's drug.
said on Thursday it will split its research and development division into two units ahead of a highly anticipated decision by the U.S. health regulator about the company's second Alzheimer's drug.
The company named interim R&D chief Priya Singhal as executive vice president, head of development following the separation. Singhal will also serve as the interim head of research till the company completes its search for a new chief for that division. Both Singhal and the new research head will report to Chief Executive Officer Christopher Viehbacher, the former Sanofi SA
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Biogen separates research and development into two functionsBiogen Inc. said Thursday that it separated research and development into two functions that report directly to new CEO Christopher Viehbacher. Priya...
Read more »
FDA set to make decision on experimental Alzheimer's drug this weekThe Food and Drug Administration is expected to decide by Friday whether to grant accelerated approval for Eisai and Biogen's experimental Alzheimer's drug, lecanemab.
Read more »
Hotflash inc: We joke about menopause, but the health risks aren't funny.hotflashinc: We joke about menopause, but the health risks aren't funny – via healthing_ca healthing healthnews womenshealth
Read more »
LeRoy Cavazos-Reyna returns to San Antonio with Localism, Inc.LeRoy Cavazos-Reyna has left the U.S. Hispanic Chamber of Commerce, but will remain focused on minority-owned business development, now in San Antonio.
Read more »
How chat bots can actually detect Alzheimer’s diseaseBots “could be a simple, accessible and adequately sensitive tool for community-based testing,” researchers say.
Read more »
UT researchers fight Alzheimer's with fitness gadgetsMedical researchers in Austin are using commercially available technology to determine who is at risk of longer-term cognitive dysfunction such as Alzheimer's disease.
Read more »